Navigation Links
Looking at AMD Through Patients' Eyes: Viscira Virtual Exhibit Educates Physicians by Personalizing Serious Eye Disease

To help eye specialists better understand the impact of one of the fastest growing eye diseases on their patients, Viscira teamed up with an industry-leading biotech company to provide physicians with a virtual experience of having neovascular (wet) age-related macular degeneration (AMD).

San Francisco, CA (PRWEB) January 29, 2009 -- To help eye specialists better understand the impact of one of the fastest growing eye diseases on their patients, Viscira teamed up with an industry-leading biotech company to provide physicians with a virtual experience of having neovascular (wet) age-related macular degeneration (AMD). Unveiled at the American Academy of Ophthalmology (AAO) annual meeting in Atlanta in November, 2008, the virtual simulation exhibit engaged physicians in the actual experience of having Wet AMD and generated data that will help physicians better treat the condition.

Developed by Viscira (, the interactive and new-media company delivering innovative technology solutions for today's pharmaceutical marketing challenges, the "EyeMac" exhibit drew meeting attendees into four viewing stations. Before beginning the simulation, attendees were surveyed using a touch-screen questionnaire to capture their Wet AMD treatment opinions and behaviors. Visitors then used special goggles to immerse themselves in the simulation environment from a first-person, patient perspective. Once the simulation was complete, viewers were asked to complete a second survey to rate the experience, including assessing if their understandings had changed and whether the virtual experience would influence their treatment approach.

"This exhibit achieved all of our objectives for the conference," said Dave Gulezian, President and CEO of Viscira. "It helped physicians better appreciate the impact of the disease on patient lives. Physicians commented that this virtual experience would be very helpful in their communication with Wet AMD patients, family members and caregivers. The exhibit also provided a unique opportunity for our client to have meaningful follow-up discussions with participants."

"Eye care specialists welcome any tools and information that can help us educate our patients and their families on this leading cause of blindness," said Richard Wong, M.D., a board-certified ophthalmologist practicing in the San Francisco Bay Area. "This exhibit and the applications that Viscira is developing will help us communicate more effectively with patients as part of a comprehensive treatment approach."

Physician Insights May Indicate Shift in Treatment Approach
Over 700 attendees at the AAO meeting viewed the EyeMac program. More than 78 percent of users said that the daily experience of a patient living with wet AMD was either significantly or somewhat different from what they had expected. More than 87 percent said that this greater awareness would significantly or somewhat change the way they would treat their patients.

Gulezian added, that, as a result of the exhibit's success at AAO, Viscira will be working with the client to deploy the virtual simulation model in other learning applications, including in the physicians' office, and in patient advocacy and sales training materials. "We are committed to fully leveraging the program across the multiple audiences involved in improving Wet AMD education and treatment," he added.

About Viscira
Viscira develops dynamic new-media communication solutions and interactive software applications for the life sciences industry. The San Francisco-based company offers a suite of best-in-class technologies that deliver engaging and memorable content via various electronic channels. Viscira provides innovative solutions for major clients such as Genentech, Amgen, Johnson & Johnson, Novartis, Eli Lilly, Allergan, Takeda and Medtronic. For more information, please visit

Karen Reina                     
The Communication Continuum            
Phone: 914.419.1307 or 845.620.0557         


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Consumers Looking to Sustainable Food Production to Feed Global Population
2. Albemarle Manufactures Zymes PTS, the Lead Compound in a Breakthrough Solubilization Technology
3. Elsevier Introduces Breakthrough Technology Intelligence Solution for Accelerating R&D and Innovation in Europe
4. Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening
5. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
6. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
7. Managing Risk Through Quality: Ansell Healthcares Innovative Gammex(R) Glove Range on Display at Arab Health 2009
8. Governor Rendell Says Life Science Industry Will Fuel New Breakthroughs, Generate Jobs for Decades to Come
9. Bell Ventures Launches Breakthrough Radical Defense Skin Care Ingredient
10. Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research
11. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
Post Your Comments:
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... the year and one of the premier annual events for pharmaceutical manufacturing: 2015 ... 8–11 November 2015, where ISPE hosted the largest number of attendees in more ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:10/29/2015)... Oct. 29, 2015   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Association (MHTA) as one of only three finalists for ... – Small and Growing" category. The Tekne Awards honor ... shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):